Outcome differences by sex in oncology clinical trials
Abstract Identifying sex differences in outcomes and toxicity between males and females in oncology clinical trials is important and has also been mandated by National Institutes of Health policies. Here we analyze the Trialtrove database, finding that, strikingly, only 472/89,221 oncology clinical...
Main Authors: | Ashwin V. Kammula, Alejandro A. Schäffer, Padma Sheila Rajagopal, Razelle Kurzrock, Eytan Ruppin |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Portfolio
2024-03-01
|
Series: | Nature Communications |
Online Access: | https://doi.org/10.1038/s41467-024-46945-x |
Similar Items
-
Reporting outcome comparisons by sex in oncology clinical trials
by: Guo Zhao, et al.
Published: (2024-04-01) -
Evolution of the Targeted Therapy Landscape for Cholangiocarcinoma: Is Cholangiocarcinoma the ‘NSCLC’ of GI Oncology?
by: Amol Gupta, et al.
Published: (2023-03-01) -
The Impact of COVID-19 on Cancer Clinical Trials Conducted by NCI-Designated Comprehensive Cancer Centers
by: Diviya Gupta, et al.
Published: (2021-05-01) -
Circulating Tumor Cells: From the Laboratory to the Cancer Clinic
by: Ruchi Agashe, et al.
Published: (2020-08-01) -
Images in Immunotherapy and Precision Oncology: Angiosarcoma of the Spleen and Liver
by: Anagha Deshpande, et al.
Published: (2023-01-01)